Cure8 research brief
This study looks at how immunomodulators are actually used with biologic drugs in real-world practice when a national reimbursement policy forces biologic interruptions.
Patients and clinicians may care because the paper reports similar remission and safety outcomes with or without continued IMMs, but different withdrawal/reinitiation patterns by disease type.
Adults with Crohn's disease or ulcerative colitis on biologic therapy; clinicians prescribing biologic–IMM combinations; researchers interested in treatment strategies and policy effects.
The researchers reviewed 280 biologic treatment courses (from 144 patients) between 2013–2025 and analyzed concomitant IMM use, withdrawal, and reinitiation using methods that account for repeated courses per patient.
Overall remission and safety event rates were not meaningfully different when IMMs were continued versus withdrawn during mandated biologic-free intervals. However, UC patients on non-anti-TNF biologics were more likely to stop IMMs and less likely to restart them compared with CD patients.
The study describes practice patterns driven in part by Taiwan's National Health Insurance reimbursement rules (a 54-week cap and required drug-free interval) rather than proving that IMMs function as an effective "bridge" therapy.
The authors call for prospective, controlled studies to test causal effects of continuing versus stopping IMMs around biologic treatment interruptions.
Results reflect practice under Taiwan's 54-week biologic reimbursement cap and mandatory drug-free interval; the study is retrospective and observational, so it cannot prove a causal bridge-therapy role for IMMs.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...
Infliximab dosing can be hard to personalize. This study shows that selecting pharmacokinetic models based on IBD type and severity can improve how well drug levels are predicted, which could help tailor dosing for...
Subcutaneous infliximab may let children on infliximab avoid regular IV infusions while keeping drug levels high and maintaining remission. Results are relevant to families and clinicians considering switching pediatric...
